The present invention provides a recombinant vector pBI-3D-hGalT or pBI-35S-hGalT containing a human β1,4-
galactosyltransferase gene; a
cell line transformed with a recombinant vector pMYN414 containing a cytotoxic T-
lymphocyte anti-gen A-immunoglobulin (CTLA4Ig)
fusion protein gene and the recombinant vector pBI-3D-hGalT or pBI-355-hGalT; and a method for producing a
plant-derived recombinant human CTLA4Ig (CTLA4Igp)
fusion protein with a human
glycan structure using the same. The
plant cell-derived recombinant human CTLA4Ig
fusion protein (CTLA4Igp), which has a human
glycan structure and is produced according to the present invention, exhibits an improved
in vivo half life as compared to conventional
plant-derived proteins, due to the presence of a human-like
glycan structure. Consequently, the present invention using the plant expression
system enables low-cost
mass production of a CTLA4Igp fusion
protein having an immunosuppressive activity comparable to that of the CTLA4IgM fusion
protein expressed in conventional animal
cell expression systems.